Peter Kurniali, MD
Hematology & Oncology · Bismarck, NDNPI 1922236793
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,787 of the $7,712 with a category attached, or 75.0%. It is spread thinly across 60 manufacturers, the largest accounting for just 23.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,527, 4.9 times the $723 reported in 2019. Among hematology & oncology clinicians in ND with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 314 payments — averaging $24.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$2K
- Daiichi Sankyo Inc.$470
- Pfizer$380
- AstraZeneca$363
- Johnson & Johnson$361
- Tempus AI, Inc$335
- plus $4K from 54 others
Across 9 payments — averaging $1434.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$10K
- Merck$3K
What the payments were for
- Consulting fees$1,65021%
- Food & beverage$5,78775%
- Education$2754%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SIR-Spheres Microspheres$136
- FOTIVDA$130
- LENVIMA$111
How this compares
$7,712 in reported general payments places this provider in the 90th percentile of 35 hematology & oncology providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 102 | $1,626,128 |
| PomalystPomalidomide | 48 | $1,007,456 |
| VenclextaVenetoclax | 26 | $321,037 |
| LenvimaLenvatinib Mesylate | 13 | $307,507 |
| CabometyxCabozantinib S-Malate | 15 | $259,852 |
| TagrissoOsimertinib Mesylate | 13 | $203,227 |
| BesremiRopeginterferon Alfa-2b-Njft | 13 | $202,689 |
| Abiraterone Acetate | 116 | $172,772 |
| XtandiEnzalutamide | 16 | $121,967 |
| EliquisApixaban | 198 | $119,424 |
| InlytaAxitinib | 11 | $110,176 |
| XareltoRivaroxaban | 58 | $45,895 |
| Enoxaparin Sodium | 22 | $5,587 |
| Hydroxyurea | 115 | $4,718 |
| Imatinib Mesylate | 15 | $3,872 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $81 | $1,626,128102 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $120 | $1,007,45648 claims |
| AbbVieVenclexta | $289 | $321,03726 claims |
| Eisai Inc.Lenvima | $250 | $307,50713 claims |
| Exelixis Inc.Cabometyx | $64 | $259,85215 claims |
| PfizerEliquis, Inlyta | $380 | $229,600209 claims |
| AstraZenecaTagrisso | $363 | $203,22713 claims |
| Pharmaessentia USA CorporationBesremi | $111 | $202,68913 claims |
| Astellas Pharma US IncXtandi | $66 | $121,96716 claims |
| Johnson & JohnsonXarelto | $361 | $45,89558 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 35 hematology & oncology providers in North Dakota.
Other hematology & oncology in Bismarck
- Matthew McGeeBismarck$3K
- Thandiwe GrayBismarck$2K
- Stewart SharpBismarck$2K
- Sagar RakshitBismarck$2K
- John ReynoldsBismarck$2K
- Alexander JohnsonBismarck$1K
- Edward WosBismarck$1K
- Aaron LuebkeBismarck$829
- David Oladele-BankoleBismarck$16
- Baruti SerabeBismarck$14
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.